new_0222_0279|AKRO|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0279|AKRO|1|Akero Therapeutics Inc Total Current Assets (Quarterly) (USD)|Akero Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Akero Therapeutics Inc Inventories (Quarterly) (USD)|Akero Therapeutics Inc Net PP&E (Quarterly) (USD)|Akero Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Akero Therapeutics Inc Total Liabilities (Quarterly) (USD)|Akero Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Akero Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Akero Therapeutics Inc Total Deposits (Quarterly) (USD)|Akero Therapeutics Inc Book Value (Quarterly) (USD)|Akero Therapeutics Inc Retained Earnings (Quarterly) (USD)|Akero Therapeutics Inc Treasury Stock (Quarterly) (USD)|Akero Therapeutics Inc EV to Revenues|Akero Therapeutics Inc EV to Earnings|Akero Therapeutics Inc EV to Free Cash Flow|Akero Therapeutics Inc EV to Assets (Quarterly)|Akero Therapeutics Inc PS Ratio|Akero Therapeutics Inc PE Ratio|Akero Therapeutics Inc Price to Book Value|Akero Therapeutics Inc PEG Ratio|Akero Therapeutics Inc Debt to Equity Ratio|Akero Therapeutics Inc Dividend Yield|Akero Therapeutics Inc Shareholder Yield (TTM)|Akero Therapeutics Inc Percent of Shares Outstanding Short|Akero Therapeutics Inc Total Receivables (Quarterly) (USD)|Akero Therapeutics Inc Total Payables (Quarterly) (USD)|Akero Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Akero Therapeutics Inc Return on Invested Capital|Akero Therapeutics Inc Quality Ratio Score|Akero Therapeutics Inc Momentum Score|Akero Therapeutics Inc Beta (1Y)|Akero Therapeutics Inc Sustainable Growth Rate (TTM)|Akero Therapeutics Inc Institutional Investor Ownership Percentage|Akero Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Akero Therapeutics Inc Total Employees (Annual)|Akero Therapeutics Inc EPS Diluted (Quarterly) (USD)|Akero Therapeutics Inc SG&A Expense (Quarterly) (USD)|Akero Therapeutics Inc Shares Outstanding|Akero Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Akero Therapeutics Inc Ordinary Shares Number (Quarterly)|Akero Therapeutics Inc Payout Ratio|Akero Therapeutics Inc Quick Ratio (Quarterly)|Akero Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Akero Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Akero Therapeutics Inc Effective Tax Rate (TTM)|Akero Therapeutics Inc Return on Equity|Akero Therapeutics Inc Net Income (TTM) (USD)|Akero Therapeutics Inc Revenue (TTM) (USD)|Akero Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Akero Therapeutics Inc Revenue (Quarterly) (USD)|Akero Therapeutics Inc Gross Profit (Quarterly) (USD)|Akero Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Akero Therapeutics Inc Net Income (Quarterly) (USD)|Akero Therapeutics Inc Net Interest Income (Quarterly) (USD)|Akero Therapeutics Inc Price (USD)|Akero Therapeutics Inc Total Return Price (USD)|Akero Therapeutics Inc Enterprise Value (USD)|Akero Therapeutics Inc 30-Day Average Daily Volume|Akero Therapeutics Inc 1 Year Price Returns (Daily)|Akero Therapeutics Inc Short Interest|Akero Therapeutics Inc PE Ratio (Forward)|Akero Therapeutics Inc PE Ratio (Forward 1y)|Akero Therapeutics Inc PS Ratio (Forward)|Akero Therapeutics Inc PS Ratio (Forward 1y)|Akero Therapeutics Inc Quarterly EPS Estimates (USD)|Akero Therapeutics Inc Quarterly Revenue Estimates (USD)|Akero Therapeutics Inc Quarterly EPS Surprise|Akero Therapeutics Inc Quarterly Revenue Surprise|Akero Therapeutics Inc Quarterly Actual EPS (USD)|Akero Therapeutics Inc Quarterly Actual Revenue (USD)|Akero Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Akero Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Akero Therapeutics Inc Price Target (USD)|Akero Therapeutics Inc Consensus Recommendation|Akero Therapeutics Inc Price Target Num Estimates|Akero Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Akero Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Akero Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Akero Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Akero Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Akero Therapeutics Inc Land and Improvements (Quarterly) (USD)|Akero Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Akero Therapeutics Inc Other Properties (Quarterly) (USD)|Akero Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0279|AKRO|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0279|AKRO|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0279|AKRO|5|91.2727272727|91.2727272727||91.2857142857||91.2727272727|91.2727272727|91.2727272727||91.2727272727|91.2727272727||||6.95714285714||||6.95714285714|||1.44725111441||15.2903225806||91.2727272727|91.2727272727|||32.2941176471|30.5263157895|||91.3571428571|100.4|91.3571428571|91.3571428571|36.7916666667||91.2727272727|||91.3571428571|91.3846153846|||91.2727272727|||||91.3571428571|91.3571428571|91.5|6.95714285714|6.95714285714|6.95714285714|6.9552238806|1.44285714286|15.2903225806|||||91.3333333333|91.3333333333|91.2857142857||91.2857142857|91.2857142857|31.8214285714|31.8214285714|21.8604651163|9.21568627451|21.8604651163|18.62|22.1666666667|91.3571428571|91.2857142857||||91.3333333333|||
new_0222_0279|AKRO|6|11|11||7||11|11|11||11|11||||140||||140|||673||62||11|11|||17|19|||14|10|14|14|24||11|||14|13|||11|||||14|14|2|140|140|140|134|420|62|||||12|12|7||7|7|28|28|43|102|43|50|42|14|7||||6|||
new_0222_0279|AKRO|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0279|AKRO|201803||||||||||||||||||||||||||||||||||21.2242||-0.0198|0.195||||||-0.0198|||||||||-0.421|-0.421|||||||||||||||||||||||||0.226||||||||
new_0222_0279|AKRO|201806||||||||||||||||||||||||||||||||||21.2242||-0.4119|0.242||||||-0.4086|||||||||-8.673|-8.673|||||||||||||||||||||||||8.42||||||||
new_0222_0279|AKRO|201809||||||||||||||||||||||||||||||||||21.2242||-0.5371|0.474||||||-0.5252|||||||||-11.148|-11.148|||||||||||||||||||||||||1.253||||||||
new_0222_0279|AKRO|201812|77.131|75.975||||127.07|2.342|124.728||-49.919|-86.565|||||||||||||||1.373||||||||21.2242|10|-2.9057|0.985|||26.2951|||-2.8963||||-81.714|||||-61.472|-61.472|||||||||||||||||||||||||1.983||||||||
new_0222_0279|AKRO|201903|70.699|69.796||||2.404|2.404|||69.662|-91.927|||||||||||||||0.952|0.002|||||||26.2951||-0.2039|1.449|||26.2951|||-0.2039||||-86.655|||||-5.362|-5.362|0.166||||||||||||||||||||||||4.063||||||||
new_0222_0279|AKRO|201906|163.108|162.654||||4.779|4.74|0.039||158.389|-99.155||||-29.3368||||7.2056|||||0.1952||3.248|0.003|||||||3.2684|10|-2.21|1.649|28.5554||28.5554|||-2.21|-97.08|||-85.21|||||-7.228|-7.228|0.381|18.56|18.56|432.1611|85686.8333||52797|||||||||||||31.25|1.5|4|-1.4903|-1.9711|5.96|||||||26.12|27.71
new_0222_0279|AKRO|201909|150.073|147.835||||6.759|6.725|0.034||143.384|-114.709||||-25.974||||3.5751|||||1.7624||0.093|0.003|||||||28.0248|10|-0.56|2.424|28.5587||28.5587|||-0.56|1.628|||-89.616|||||-15.554|-15.554|0.755|19.83|19.83|403.5996|134419.5333||503304|||||||||||||32|1.5|4|-2.6864|-2.2809|13.885|||||||20.99|19.69
new_0222_0279|AKRO|201912|138.049|136.4||||9.392|9.369|0.023||128.726|-130.32||||-19.0444||||4.597|||||2.3448||0.947|0.003|||||||28.5678|14|-0.55|3.083|28.5678||28.5678|||-0.55||||-43.755|||||-15.611|-15.611||23.08|23.08|511.2998|133689.6667||669870|||||-0.5849||5.9733||-0.55||||34.6|1.5|5|-2.7411||13.138|||||||24.69|21.77
new_0222_0279|AKRO|202003|126.218|125.285||0.226||8.298|8.286|0.012||118.323|-142.206||||-9.79||||3.7181|||||2.8556||1.535|0.003|||||||28.4995|14|-0.42|3.588|28.6712||28.6712|||-0.42||||-50.279|||||-11.886|-11.886||16.73|16.73|342.2102|239636.8||818733|||||-0.61||31.1475||-0.42||||34.3333|1.5|6|-2.37|-2.688|8.791|||||0.226||21.5|24.93
new_0222_0279|AKRO|202006|113.193|102.833||||10.395|10.393|0.002||103.663|-158.413||||-14.4063||||5.942|||||3.9039||2.536|0.003|||9|0.3033|||28.603|13|-0.57|3.417|28.6837||28.6837|||-0.57||||-59.258|||||-16.207|-16.207||24.52|24.52|577.7917|230644.5333|30.1305|1119768|||||-0.6177||7.7252||-0.57||||32.6|1.4|5|-1.8674|-2.6699|13.037|||||||36.12|31.65
new_0222_0279|AKRO|202009|298.033|291.87||1.847||13.578|12.014|1.564||286.458|-179.816||||-17.2356||||10.501|||||3.9085||4.636|0.004|||7|0.6269|||34.0028|17|-0.63|4.159|34.7207||34.7207|||-0.63|-202.554|||-65.107|||||-21.403|-21.403||32.15|32.15|985.7311|162215.5|35.3407|1357060|||||-0.671||6.1103||-0.63||||62.1429|1.4286|7|-2.6966|-2.4839|17.379|0.006||||1.847||26.5|29.23
new_0222_0279|AKRO|202012|271.345|268.387||1.793||14.627|13.111|1.516||258.712|-209.527||||-10.102||||3.0448|||||7.2844||3.428|0.004|||8|0.7065|||34.708|21|-0.86|4.074|34.7416||34.7416|||-0.86||||-79.207|||||-29.711|-29.711||25.63|25.63|580.3416|223375.2333|16.2424|2530734|||||-0.5955||-44.4092||-0.86||||60.2857|1.4286|7|-2.2161|-2.6504|25.709|0.011||||1.793||30.01|30.27
new_0222_0279|AKRO|202103|255.776|249.984||1.732||11.603|10.136|1.467||246.02|-224.617||||-10.1349||||3.8169|||||8.2557||4.605|0.004|||6|0.5688|||34.7443|21|-0.43|4.526|34.7703||34.7703|||-0.43||||-82.411|||||-15.09|-15.09||28.4|28.4|719.0895|277597.1|36.8396|2870517|||||-0.936||54.0608||-0.43||||60.125|1.375|8|-4.2104|-4.5851|10.602|0.011||||1.732||30.73|25.73
new_0222_0279|AKRO|202106|236.222|230.028||1.672||17.876|16.459|1.417||220.133|-253.55||||-8.2473||||3.6253|||||9.8688||2.307|0.004|||3|1.2305|||34.8146|28|-0.83|4.99|34.8408||34.8408|||-0.83||||-95.137|||||-28.933|-28.933||25.61|25.61|641.9124|269973.3|-0.4414|3438361|||||-0.7056||-17.6221||-0.83||||57.1429|1.375|7|-2.9139|-3.0347|23.976|0.01||||1.672||21.4|23.74
new_0222_0279|AKRO|202109|221.807|215.081||1.612||24.905|23.54|1.365||198.628|-277.88||||-7.6231||||3.652|||||7.9869||6.784|0.004|||2|0.9009|||34.8621|32|-0.7|4.883|34.8753||34.8753|||-0.7||||-98.064|||||-24.33|-24.33||23.06|23.06|573.8874|176796.1333|-27.4115|2785447|||||-0.9068||22.8038||-0.7||||54.7143|1.4286|7|-3.1842|-3.6455|19.47|0.009||||1.612||21.56|21.26
new_0222_0279|AKRO|202112|||||||||||||||-6.863||||3.7219|||||10.8789||||||3|0.1588||||||||||||||||||||||||21.19|21.19|524.2021|221096.4|-18.0233|3795449|||||-0.8083||||||||47|1.6667|6|-2.7575|-3.5396||||||||19.64|17.74
new_0222_0279|AKRO|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.835|||||||||||||||||||||
new_0222_0279|AKRO|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.865|||||||||||||||||||||
new_0222_0279|AKRO|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.84|||||||||||||||||||||
new_0222_0279|AKRO|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.8|||||||||||||||||||||